We are a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx) TM in oncology and inflammation. Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMAR xT Tissue-Specific TM Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. Our pipeline includes pre-clinical tissue-specific therapeutics to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. We use systems biology principles for rapid candidate selection and effective pre-clinical studies, leading to efficient manufacturing/scale up processes, toxicology and IP, followed by selection of appropriate contract research organizations and high-speed enrollment clinical trial sites.
General form for registration of securities under the Securities Act of 1933
Draft Registration Statement